The impacts of epirubicin and liposome doxorubicin on human breast cancer cell lines and dentritic cells
- VernacularTitle:表柔比星、脂质体多柔比星单药对乳腺癌细胞和树突状细胞生长的抑制作用
- Author:
Fang YU
;
Ling WANG
;
Qing YAO
- Publication Type:Journal Article
- Keywords:
breast cancer;
dendritic cell;
epirubicin;
liposome doxorubicin
- From:
China Oncology
2001;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:Epirubicin is one of the fi rst line chemotherapy drugs in the treatment of breast cancer, and liposome doxorubicin is a new antitumor drug that has been reported to have less cardiotoxicity and myelosuppression compared to free doxorubicin. Dentritic cells (DC) play important roles in tumor immunity. Our experiment investigated the impacts of epirubicin and liposome doxorubicin on different human breast cancer cell lines and dentritic cells, and evaluated their roles in the treatment of breast cancer. Methods:Human breast cancer cell lines, Bcap37 and MDA-MB-231, along with human dentritic cells isolated and induced into maturation, were cultured with epirubicin and liposome adriamycin at different concentrations (0, 0.25, 0.5, 1.0, 2.0, 4.0, 10.0 ?g/ml), respectively. The inhibitory effects were detected by MTT method after 24, 48, 72 h. Results:Epirubicin and liposome adriamycin could inhibit the proliferation of Bcap37 cells, MDA-MB-231 cells, and human dentritic cells. Liposome adriamycin exhibited a lighter inhibition on dentritic cells than on human breast cancer cell lines (Bcap37 and MDA- MB-231) (F=22.208, P
